PA
SYRE icon

Profund Advisors’s Spyre Therapeutics SYRE Stock Holding History

Profund Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Sell
19,419
-6,624
-25% -$483K 0.05% 233
2026
Q1 		$1.31M Buy
26,043
+5,450
+26% +$205K 0.05% 273
2025
Q4 		$675K Buy
20,593
+7,370
+56% +$193K 0.02% 458
2025
Q3 		$222K Buy
13,223
+2,180
+20% +$35.5K 0.01% 921
2025
Q2 		$165K Sell
11,043
-3,619
-25% -$53.5K 0.01% 932
2025
Q1 		$237K Sell
14,662
-200
-1% -$4.16K 0.01% 820
2024
Q4 		$346K Buy
14,862
+787
+6% +$23.1K 0.01% 694
2024
Q3 		$414K Buy
14,075
+1,469
+12% +$40.9K 0.02% 616
2024
Q2 		$296K Buy
+12,606
New +$425K 0.01% 725

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Profund Advisors's SYRE Position: Q2 2026 in Review

Profund Advisors reduced its Spyre Therapeutics (SYRE) stake by 25% in Q2 2026, selling an estimated $483K and leaving 19,419 shares worth $1.72M. The position accounts for 0.05% of the portfolio, ranked #233.

Profund Advisors first reported a position in SYRE in Q2 2024 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Profund Advisors held 19,419 shares of Spyre Therapeutics worth $1.72M as of Q2 2026.
  • Profund Advisors sold 6,624 Spyre Therapeutics shares in Q2 2026, an estimated $483K.
  • Spyre Therapeutics made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #233 holding.
  • Profund Advisors first reported a position in Spyre Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.